The most significant finding from the current study is the association between variant TGFβ1 genotypes at rs1800469 and rs1982073 and worse DMFS among patients with NSCLC given radiotherapy; this finding suggests that SNPs in TGFβ1 genes could be used as biomarkers to prescribe personalized radiochemotherapy according to the expected pattern of recurrence before the initiation of treatment. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.